OMS: enfermedad desatendida | 14 ABR 19

Día Mundial del Chagas

La enfermedad de Chagas es una antropozoonosis del continente americano que se ha expandido más allá de sus límites originales debido a las migraciones. La OMS considera a la enfermedad de Chagas como una enfermedad desatendida
Autor/a: José A Pérez-Molina, Israel Molina The Lancet Volume 391, No. 10115
INDICE:  1. Página 1 | 2. Referencias bibliográficas
Referencias bibliográficas

1 WHO. First WHO report on neglected tropical diseases: working to overcome the global impact of neglected tropical diseases. WHO/HTM/NTD/2010. Geneva: World Health Organization, 2010.

2 Ventura-Garcia L, Roura M, Pell C, et al. Socio-cultural aspects of Chagas disease: a systematic review of qualitative research. PLoS Negl Trop Dis 2013; 7: e2410.

3 Conteh L, Engels T, Molyneux DH. Socioeconomic aspects of neglected tropical diseases. Lancet 2010; 375: 239–47.

4 Lee BY, Bacon KM, Bottazzi ME, Hotez PJ. Global economic burden of Chagas disease: a computational simulation model. Lancet Infect Dis 2013; 13: 342–48.

5 Schmunis GA, Schmunis GA, Yadon ZE. Chagas disease: a Latin American health problem becoming a world health problem. Acta Trop 2010; 115: 14–21.

6 Requena-Mendez A, Aldasoro E, de Lazzari E, et al. Prevalence of Chagas disease in Latin-American migrants living in Europe: a systematic review and meta-analysis. PLoS Negl Trop Dis 2015; 9: e0003540.

7 Bern C, Montgomery SP. An estimate of the burden of Chagas disease in the United States. Clin Infect Dis 2009; 49: e52–54.

8 Zingales B, Miles MA, Campbell DA, et al. The revised Trypanosoma cruzi subspecific nomenclature: rationale, epidemiological relevance and research applications. Infect Genet Evol 2012; 12: 240–53.

9 Yamagata Y, Nakagawa J. Control of Chagas disease. Adv Parasitol 2006; 61: 129–65.

10 WHO. Control of Chagas disease: second report of the WHO expert Committee. WHO technical report series, 905. Geneva: World Health Organization, 2002.

11 Howard EJ, Xiong X, Carlier Y, Sosa-Estani S, Buekens P. Frequency of the congenital transmission of Trypanosoma cruzi: a systematic review and meta-analysis. BJOG 2014; 121: 22–33.

12 Luquetti AO, Tavares SBDN, Siriano LDR, et al. Congenital transmission of Trypanosoma cruzi in central Brazil. A study of 1,211 individuals born to infected mothers. Mem Inst Oswaldo Cruz 2015; 110: 369–76.

13 Murcia L, Carrilero B, Munoz-Davila MJ, Thomas MC, López MC, Segovia M. Risk factors and primary prevention of congenital Chagas disease in a nonendemic country. Clin Infect Dis 2013; 56: 496–502.

14 Bern C, Verastegui M, Gilman RH, et al. Congenital Trypanosoma cruzi transmission in Santa Cruz, Bolivia. Clin Infect Dis 2009; 49: 1667–74.

15 Bua J, Volta BJ, Velazquez EB, Ruiz AM, Rissio AMD, Cardoni RL. Vertical transmission of Trypanosoma cruzi infection: quantification of parasite burden in mothers and their children by parasite DNA amplification. Trans R Soc Trop Med Hyg 2012; 106: 623–28.

16 Kaplinski M, Jois M, Galdos-Cardenas G, et al. Sustained domestic vector exposure is associated with increased Chagas cardiomyopathy risk but decreased parasitemia and congenital transmission risk among young women in Bolivia. Clin Infect Dis 2015; 61: 918–26.

17 Bern C, Montgomery SP, Katz L, Caglioti S, Stramer SL. Chagas disease and the US blood supply. Curr Opin Infect Dis 2008; 21: 476–82.

18 Cancino-Faure B, Fisa R, Riera C, Bula I, Girona-Llobera E, Jimenez-Marco T. Evidence of meaningful levels of Trypanosoma cruzi in platelet concentrates from seropositive blood donors. Transfusion 2015; 55: 1249–55.

19 Riarte A, Luna C, Sabatiello R, et al. Chagas’ disease in patients with kidney transplants: 7 years of experience 1989–1996. Clin Infect Dis 1999; 29: 561–67.

20 Cicora F, Escurra V, Silguero S, González IM, Roberti JE. Use of kidneys from Trypanosoma Cruzi-infected donors in naive transplant recipients without prophylactic therapy. Transplantation 2014; 97: e3–4.

21 Huprikar S, Bosserman E, Patel G, et al. Donor-derived Trypanosoma cruzi infection in solid organ recipients in the United States, 2001–2011. Am J Transplant 2013; 13: 2418–25.

22 Chin-Hong PV, Schwartz BS, Bern C, et al. Screening and treatment of Chagas disease in organ transplant recipients in the United States: recommendations from the Chagas in Transplant Working Group. Am J Transplant 2011; 11: 672–80.

23 Kun H, Moore A, Mascola L, et al. Transmission of Trypanosoma cruzi by heart transplantation. Clin Infect Dis 2009; 48: 1534–40.

24 Alarcón de Noya B, Díaz Bello Z, Colmenares C, et al. Large urban outbreak of orally acquired acute Chagas disease at a school in Caracas, Venezuela. J Infect Dis 2010; 201: 1308–15.

25 Herwaldt BL. Laboratory-acquired parasitic infections from accidental exposures. Clin Microbiol Rev 2001; 14: 659–88.

26 Feliciangeli MD, Campbell-Lendrum D, Martinez C, Gonzalez D, Coleman P, Davies C. Chagas disease control in Venezuela: lessons for the Andean region and beyond. Trends Parasitol 2003; 19: 44–49.

27 Samuels AM, Clark EH, Galdos-Cardenas G, et al. Epidemiology of and impact of insecticide spraying on Chagas disease in communities in the Bolivian Chaco. PLoS Negl Trop Dis 2013; 7: e2358.

28 Bowman NM, Kawai V, Levy MZ, et al. Chagas disease transmission in periurban communities of Arequipa, Peru. Clin Infect Dis 2008; 46: 1822–28.

29 WHO. Chagas disease in Latin America: an epidemiological update based on 2010 estimates. Wkly Epidemiol Rec 2015; 90: 33–43.

30 Bern C, Kjos S, Yabsley MJ, Montgomery SP. Trypanosoma cruzi and Chagas’ disease in the United States. Clin Microbiol Rev 2011; 24: 655–81.

31 Hernandez S, Flores CA, Viana GM, Sanchez DR, Traina MI, Meymandi SK. Brief Report: Autochthonous Transmission of Trypanosoma cruzi in Southern California. Open Forum Infect Dis 2016; 3: ofw227.

32 Moncayo A, Silveira AC. Current epidemiological trends for Chagas disease in Latin America and future challenges in epidemiology, surveillance and health policy. Mem Inst Oswaldo Cruz 2009; 104: 17–30.

33 Organizacion Panamericana de la Salud. Estimación cuantitativa de la enfermedad de Chagas en las Américas. OP5/HDM/CD/425- 0G 2006. (accessed May 29, 2017).

34 Salvatella R, Irabedra P, Castellanos LG. Interruption of vector transmission by native vectors and the art of the possible. Mem Inst Oswaldo Cruz 2014; 109: 122–30.

35 Shikanai-Yasuda MA, Carvalho NB. Oral transmission of Chagas disease. Clin Infect Dis 2012; 54: 845–52.

36 Gurevitz JM, Gaspe MS, Enriquez GF, Provecho YM, Kitron U, Gürtler RE. Intensified surveillance and insecticide-based control of the Chagas disease vector Triatoma infestans in the Argentinean Chaco. PLoS Negl Trop Dis 2013; 7: e2158.

37 Basile L, Jansa JM, Carlier Y, et al. Chagas disease in European countries: the challenge of a surveillance system. Euro Surveill 2011; 16: pii 19968.

38 Stimpert KK, Montgomery SP. Physician awareness of Chagas disease, USA. Emerging Infect Dis 2010; 16: 871–72.

39 Wegner DH, Rohwedder RW. The effect of nifurtimox in acute Chagas’ infection. Arzneimittelforschung 1972; 22: 1624–35.

40 Laranja FS, Dias E, Nobrega G, Miranda A. Chagas’ disease. A clinical, epidemiologic, and pathologic study. Circulation 1956; 14: 1035–60.

41 Pinto AY, Valente SA, Valente VDC, Ferreira Junior AG, Coura JR. Acute phase of Chagas disease in the Brazilian Amazon region: study of 233 cases from Pará, Amapá and Maranhão observed between 1988 and 2005. Rev Soc Bras Med Trop 2008; 41: 602–14 (in Portuguese).

42 Bittencourt AL, Sadigursky M, Barbosa HS. Congenital Chagas’ disease. Study of 29 cases. Rev Inst Med Trop Sao Paulo 1975; 17: 146–59 (in Portuguese).

43 Dias JC. The indeterminate form of human chronic Chagas’ disease. A clinical epidemiological review. Rev Soc Bras Med Trop 1989; 22: 147–56.

44 Viotti RJ, Vigliano C, Laucella S, et al. Value of echocardiography for diagnosis and prognosis of chronic Chagas disease cardiomyopathy without heart failure. Heart 2004; 90: 655–60.

45 Rochitte CE, Oliveira PF, Andrade JM, et al. Myocardial delayed enhancement by magnetic resonance imaging in patients with Chagas’ disease. J Am College Cardiol 2005; 46: 1553–58.

46 Pérez-Ayala A, Pérez-Molina JA, Norman FF, Monge-Maillo B, Faro MV, López-Vélez R. Gastro-intestinal Chagas disease in migrants to Spain: prevalence and methods for early diagnosis. Ann Trop Med Parasitol 2011; 105: 25–29.

47 Coura JR, de Abreu LL, Pereira JB, Willcox HP. Morbidity in Chagas’ disease. IV. Longitudinal study of 10 years in Pains and Iguatama, Minas Gerais, Brazil. Mem Inst Oswaldo Cruz 1985; 80: 73–80 (in Portuguese).

48 Espinosa R, Carrasco HA, Belandria F, et al. Life expectancy analysis in patients with Chagas’ disease: prognosis after one decade (1973–1983). Int J Cardiol 1985; 8: 45–56.

49 Sabino EC, Ribeiro AL, Salemi VMC, et al. Ten-year incidence of Chagas cardiomyopathy among asymptomatic Trypanosoma cruzi-seropositive former blood donors. Circulation 2013; 127: 1105–15.

50 Viotti R, Vigliano C, Lococo B, et al. Long-term cardiac outcomes of treating chronic Chagas disease with benznidazole versus no treatment: a nonrandomized trial. Ann Intern Med 2006; 144: 724–34.

51 Machado-de-Assis GF, Diniz GA, Montoya RA, et al. A serological, parasitological and clinical evaluation of untreated Chagas disease patients and those treated with benznidazole before and thirteen years after intervention. Mem Inst Oswaldo Cruz 2013; 108: 873–80.

52 Pérez-Ayala A, Pérez-Molina JA, Norman FF, et al. Chagas disease in Latin American migrants: a Spanish challenge. Clin Microbiol Infect 2011; 17: 1108–13.

53 Salvador F, Treviño B, Sulleiro E, et al. Trypanosoma cruzi infection in a non-endemic country: epidemiological and clinical profile. Clin Microbiol Infect 2014; 20: 706–12.

54 Rassi A, Little WC. Chagas’ heart disease. Clin Cardiol 2000; 23: 883–89.

55 Rassi A Jr, Rassi SG, Rassi A. Sudden death in Chagas’ disease. Arq Bras Cardiol 2001; 76: 75–96.

56 Hidron AI, Gilman RH, Justiniano J, et al. Chagas cardiomyopathy in the context of the chronic disease transition. PLoS Negl Trop Dis 2010; 4: e688.

57 Rassi A, Rassi SG. Predictors of mortality in chronic Chagas disease: a systematic review of observational studies. Circulation 2007; 115: 1101–08.

58 de Oliveira RB, Troncon LE, Dantas RO, Menghelli UG. Gastrointestinal manifestations of Chagas’ disease. Am J Gastroenterol 1998; 93: 884–9.

59 Cardoso RN, Macedo FYB, Garcia MN, et al. Chagas cardiomyopathy is associated with higher incidence of stroke: a meta-analysis of observational studies. J Card Fail 2014; 20: 931–38.

60 Nunes MCP, Barbosa MM, Ribeiro ALP, Barbosa FBL, Rocha MOC. Ischemic cerebrovascular events in patients with Chagas cardiomyopathy: a prospective follow-up study. J Neurol Sci 2009; 278: 96–101.

61 Carod-Artal FJ. Policy implications of the changing epidemiology of Chagas disease and stroke. Stroke 2013; 44: 2356–60.

62 Sica RE, Gonzalez Cappa SM, Sanz OP, Mirkin G. Peripheral nervous system involvement in human and experimental chronic American trypanosomiasis. Bull Soc Pathol Exot 1995; 88: 156–63.

63 Bonney KM, Engman DM. Chagas heart disease pathogenesis: one mechanism or many? Curr Mol Med 2008; 8: 510–18.

64 Tarleton RL. Parasite persistence in the aetiology of Chagas disease. Int J Parasitol 2001; 31: 550–54.

65 Burgos JM, Diez M, Vigliano C, et al. Molecular identification of Trypanosoma cruzi discrete typing units in end-stage chronic Chagas heart disease and reactivation after heart transplantation. Clin Infect Dis 2010; 51: 485–95.

66 Dutra WO, Menezes CAS, Magalhães LMD, Gollob KJ. Immunoregulatory networks in human Chagas disease. Parasite Immunol 2014; 36: 377–87.

67 Machado FS, Dutra WO, Esper L, et al. Current understanding of immunity to Trypanosoma cruzi infection and pathogenesis of Chagas disease. Semin Immunopathol 2012; 34: 753–70.



Para ver los comentarios de sus colegas o para expresar su opinión debe ingresar con su cuenta de IntraMed.

Términos y condiciones de uso | Todos los derechos reservados | Copyright 1997-2023